Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Establishment Labs Holdings Inc. has received a consensus rating of "Moderate Buy" from five brokerages, with one hold and four buy ratings.
• The average 12-month target price for Establishment Labs is $55.80, reflecting positive sentiment from analysts despite recent mixed performance.
• In its latest earnings report, the company missed EPS estimates, reporting a loss of ($0.57), but experienced a 16.1% increase in revenue year-over-year, totaling $51.30 million.

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $55.80.

A number of research analysts have weighed in on the company. Needham & Company LLC restated a "buy" rating and issued a $48.00 price objective on shares of Establishment Labs in a report on Friday, June 13th. Wall Street Zen lowered Establishment Labs from a "hold" rating to a "sell" rating in a report on Saturday. BTIG Research assumed coverage on Establishment Labs in a report on Friday, May 16th. They issued a "buy" rating and a $62.00 price objective on the stock. Mizuho raised their price objective on Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. Finally, Citigroup raised their price objective on Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a report on Wednesday, July 9th.

Institutional Trading of Establishment Labs

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Establishment Labs by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company's stock worth $1,105,000 after acquiring an additional 299 shares during the last quarter. Patriot Financial Group Insurance Agency LLC increased its stake in shares of Establishment Labs by 5.2% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,025 shares of the company's stock worth $257,000 after acquiring an additional 300 shares during the last quarter. Raymond James Financial Inc. increased its stake in shares of Establishment Labs by 0.4% in the 1st quarter. Raymond James Financial Inc. now owns 119,752 shares of the company's stock worth $4,886,000 after acquiring an additional 491 shares during the last quarter. Swiss National Bank increased its stake in shares of Establishment Labs by 1.3% in the 1st quarter. Swiss National Bank now owns 39,000 shares of the company's stock worth $1,591,000 after acquiring an additional 500 shares during the last quarter. Finally, Quarry LP acquired a new stake in shares of Establishment Labs in the 4th quarter worth $27,000. 72.91% of the stock is owned by institutional investors and hedge funds.

Establishment Labs Trading Up 1.0%

Shares of ESTA opened at $38.32 on Friday. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $50.85. The stock has a market capitalization of $1.11 billion, a PE ratio of -12.56 and a beta of 0.83. The company has a debt-to-equity ratio of 9.71, a quick ratio of 1.67 and a current ratio of 2.84. The company's fifty day moving average is $40.78 and its 200 day moving average is $37.08.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.03). Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The business had revenue of $51.30 million for the quarter, compared to analysts' expectations of $50.80 million. During the same quarter last year, the business earned ($0.62) EPS. The company's quarterly revenue was up 16.1% on a year-over-year basis. Sell-side analysts expect that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.